Pimurutamab

匹姆瑞妥单抗

Report date: 2026/04/05 20:00:15

Base Information

Drug NamePimurutamab
Drug Alias NameHumanized anti-EGFR monoclonal antibody (Shanghai Henlius Biotech)重组抗EGFR人源化单克隆抗体(上海复宏汉霖)Recombinant humanized anti-EGFR mAB(Shanghai Henlius Biotech)重组抗EGFR人源化单克隆抗体注射液(上海复宏汉霖)HLX-07
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[16] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShanghai Henlius Biotech Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Henlius Biologics Co LtdWuhan Union HospitalShanghai Henlius Biotech Inc
Inactive CompaniesHenlix IncShanghai Henlius Biopharmaceuticals Co Ltd
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms +[13] 
Inactive IndicationsSmall Cell Lung CarcinomaStomach NeoplasmsEsophageal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A